AZD2014 and Weekly Paclitaxel in Squamous NSCLC

• ClinicalTrials.gov Identifier: NCT02403895
• Recruitment Status: Terminated
• First Posted: March 31, 2015
• Results First Posted: July 3, 2018
• Last Update Posted: July 3, 2018
• Sponsor: AstraZeneca
• Information provided by (Responsible Party): AstraZeneca

Tracking Information

• First Submitted Date: March 7, 2015
• First Posted Date: March 31, 2015
• Results First Submitted Date: December 22, 2017
• Results First Posted Date: July 3, 2018
• Last Update Posted Date: July 3, 2018
• Actual Study Start Date: April 15, 2015
• Actual Primary Completion Date: December 29, 2016 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 4, 2018)

Percentage of Patients Who Have a Partial Response or Complete Response Through Measurement of Tumour Lesion Sizes [ Time Frame: From first dose until disease progression (Approximately 3 months) ]

Calculation of the percentage of patient who have a Complete Response or Partial Response to treatment which is confirmed by a repeat assessment 4 weeks later

Original Primary Outcome Measures (submitted: March 26, 2015)

Anti-tumour activity through calculation of the percentage of patients who have a Partial Response or Complete response through measurement of tumour lesion sizes [ Time Frame: From first dose until disease progression (Approximately 3 months) ]

Calculation of the percentage of patient who have a Complete Response or Partial Response to treatment which is confirmed by a repeat assessment 4 weeks later

Current Secondary Outcome Measures (submitted: June 4, 2018)

• Number of Patients Who Experienced at Least One Adverse Event (AE) or Serious Adverse Event (SAE) [ Time Frame: Informed consent until end of safety follow up (Approx 10 months if all treatment cycles are completed) ]
  The safety and tolerability of AZD2014 with weekly paclitaxel as assessed with the collection of Adverse Events and Serious Adverse Events as reported during clinic visits. In addition, clinical assessments were made throughout the on treatment period including blood test for chemistry, haematology, and blood clotting. In addition to clinical observations such as vital signs, and cardiac function through the use of ECG. Any findings from the above assessments which were considered to be abnornal and clinically significant by the doctor were reported as (AEs or SAEs).
• Overall Survival: Median Number of Days Between the First Dose and End of Life Due to Any Cause [ Time Frame: From first dose until end of life (Approx 9 months) ]
  Assessment of the duration of overall survival in weeks through direct patient follow-up. Any patient not known to have died at the time of analysis censored at the last recorded date the patient was known to be alive
• Best Objective Response: Number of Patients Who Experienced a Best Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), Not-Evaluable (NE), Through Measurement of Tumour Lesion Sizes. [ Time Frame: From Baseline until Disease Progression (Approx 3 months) ]
  Per Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed through imaging (CT or MRI scan) or clinical examination; Complete Response (CR): Disappearance of all target lesions; Partial Response (PR) >=30% decrease in sum of target lesion longest diameter; Progressive Disease >=20% increase in sum of target lesion longest diameter; Stable Disease (SD) increase or decrease amounting to neither PR or PD. Overall tumour assessment based on quantitative assessment of target lesions and qualitative assessment of non-target lesions in line with RECIST criteria.
• Duration of Response: Median Number of Days From the Date of First Documented Response Until the Date of Documented Progression Through Measurement of Tumour Lesion Sizes [ Time Frame: From date of first documented response until documented progression or end of life in the absence of progression (Approx 3 months) ]
  Assessment of the duration of tumour response through assessment of tumour lesions by RECIST 1.1 criteria. Response is defined as the point at which the criteria for Partial Response (PR) was met) >=30% decrease in sum of target lesion longest diameter. Progression is defined as the point at which the criteria for Progressive Disease (PD) was met >=20% increase in sum of target lesion longest diameter, or until end of life.
• Disease Control Rate: Percentage of Patients Who Achieve Partial Response, Complete Response or Stable Disease Through Assessment of Tumour Lesion Sizes [ Time Frame: From first dose until documented progression and at least 6 weeks after the start of treatment for assessment of Stable Disease - Assessed at 6, 13 and 20 Weeks ]
  Assessment of the disease control rate, percentage of patients who experience a response through assessment of tumour lesions by RECIST 1.1 criteria
• Change in Tumour Size: Median Percentage Change in Tumour Size in mm by Measurement of Tumour Lesion Sizes [ Time Frame: From baseline until documented progression (Approx 3 months) ]
  Assessment of the degree of tumour response through measurement of the change in tumour lesion sizes
• Progression Free Survival: Median Number of Days Between Start of Dosing Until Objective Disease Progression Through Measurement of Tumour Lesion Sizes [ Time Frame: From date of first dose until documented progression or end of life (Approx 3 months) ]
  Assessment of the duration of progression free survival through assessment of tumour lesions by RECIST 1.1 criteria
• Evaluate the Effect of the Combination of AZD2014 and Paclitaxel on Pharmacokinetics Assessment of Cmax [ Time Frame: Assessment at multiple timepoints in Group A patients. Samples will be taken at pre-dose and at 10 further timepoints on day 1 and at pre-dose and 9 further timepoints on days 3 and 8 ]
  To determine the effect of co-administration of paclitaxel on the PK of oral AZD2014 and the effect of co administration of oral AZD2014 on the PK of paclitaxel (Group A) by: PK parameters for each in the presence and absence of the other by intensive PK sampling and NCA techniques.
• Estimated Pharmacokinetic Exposure to AZD2014 Through the Use of Population PK Modelling [ Time Frame: Assessment at multiple timepoints in Group B patients between study day 1 and day 3. Samples will be taken at 3 points on day 1 and at predose and at a further 2 points on day 3 ]
  Group B patients: PK parameters for AZD2014 estimated from a sparse PK sampling regimen and use of population PK modelling techniques (may be reported outside the clinical study report (CSR))

Original Secondary Outcome Measures (submitted: March 26, 2015)

• Number of patients experiencing adverse events (AE) and Serious Adverse Events (SAEs) including chemistry, haematology, vital signs and ECG variables [ Time Frame: Informed consent until end of safety follow up (Approx 10 months if all treatment cycles are completed) ]
  The safety and tolerability of AZD2014 with weekly paclitaxel will be assessed with the collection of AEs/SAEs, clinical chemistry/haematology/coagulation, vital signs, and ECG parameters
• Duration of Overall Survival [ Time Frame: From first dose until end of life (Approx 9 months) ]
  Assessment of the duration of overall survival through patient follow-up
• Anti-tumour activity through assessment of Best Objective Response by assessment of tumour lesions [ Time Frame: From Baseline until Disease Progression (Approx 3 months) ]
  Assessment of the best tumour response through assessment of tumour lesions by RECIST 1.1 criteria
• Anti-tumour activity through assessment of Duration of Response by assessment of tumour lesions [ Time Frame: From date of first documented response until documented progression or end of life in the absence of progression (Approx 3 months) ]
  Assessment of the duration of tumour response through assessment of tumour lesions by RECIST 1.1 criteria
• Anti-tumour activity through assessment of Disease Control Rate by measurement of the number of patients who achieve Partial Response, Complete Response or Stable Disease through assessment of tumour lesions [ Time Frame: From first dose until documented progression and at least 7 weeks after the start of treatment for assessment of Stable Disease (Approx 3 months) ]
  Assessment of the disease control rate, number of patients who experience a response through assessment of tumour lesions by RECIST 1.1 criteria
• Anti-tumour activity through assessment of percentage change in tumour size by measurement of tumour lesions [ Time Frame: From baseline until documented progression (Approx 3 months) ]
  Assessment of the degree of tumour response through measurement of the change in tumour lesion sizes
• Anti-tumour activity through assessment of duration of progression free survival by measurement of tumour lesions [ Time Frame: From date of first dose until documented progression or end of life (Approx 3 months) ]
  Assessment of the duration of progression free survival through assessment of tumour lesions by RECIST 1.1 criteria
• Evaluate the effect of the combination of AZD2014 and paclitaxel on pharmacokinetics which may include assessment of AUC (Area Under Curve) and levels of plasma concentration over time (Cmax, tmax, tlast, Cinf) [ Time Frame: Assessment at multiple timepoints in Group A patients. Samples will be taken at pre-dose and at 10 further timepoints on day 1 and at pre-dose and 9 further timepoints on days 3 and 8 ]
  To determine the effect of co-administration of paclitaxel on the PK of oral AZD2014 and the effect of co administration of oral AZD2014 on the PK of paclitaxel (Group A) by: PK parameters for each in the presence and absence of the other by intensive PK sampling and NCA techniques.
• Estimated pharmacokinetic exposure to AZD2014 through the use of population PK modelling [ Time Frame: Assessment at multiple timepoints in Group B patients between study day 1 and day 3. Samples will be taken at 3 points on day 1 and at predose and at a further 2 points on day 3 ]
  Group B patients: PK parameters for AZD2014 estimated from a sparse PK sampling regimen and use of population PK modelling techniques (may be reported outside the clinical study report (CSR))

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: AZD2014 and Weekly Paclitaxel in Squamous NSCLC
• Official Title: A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients With Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After At Least One Line of Prior Therapy
• Brief Summary: Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)

Detailed Description

This is an open-label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of the combination of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC) that is relapsed or refractory to conventional treatment after at least 1 prior treatment with standard of care (SOC) and for whom weekly paclitaxel treatment is an appropriate treatment choice.

The study will simultaneously enrol patients to the following two groups. Group A (intensive PK) will enrol 10 evaluable patients for an intra-patient evaluation of the impact of paclitaxel on exposure to AZD2014, and the impact of AZD2014 on exposure to paclitaxel via intensive PK sampling and non-compartmental PK analysis techniques (NCA). Group B (sparse PK) will enrol 30 patients and sparse sampling and population PK modelling techniques will be employed to estimate exposure to AZD2014 when administered in combination with a weekly paclitaxel dosing regimen. The efficacy and safety of the AZD2014 and weekly paclitaxel combination will be evaluated in all 40 patients using RECIST 1.1, observation of AEs/SAEs and use of conventional safety parameters.

Eligible patients will receive study treatment consisting of a single weekly paclitaxel infusion (80 mg/m2) on Day 1 of each week and twice daily (BD) 50 mg doses of AZD2014 on the first 3 days each week for 6 weeks [except Group A patients in Week 1 of Cycle 1 who will take 50 mg BD doses of AZD2014 on Days 3, 4 and 5 (or Days 4, 5 and 6) to accommodate PK sampling], followed by a break from treatment when no paclitaxel or AZD2014 will be given. This 7-week schedule composes one cycle of treatment. AZD2014 will be administered as oral tablets to fasted patients (i.e., no food 2 hours before and 1 hour after each dose). Patients will receive up to 6 cycles of paclitaxel, although additional cycles of paclitaxel may be given if deemed appropriate by the Investigator.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Squamous Non Small Cell Lung Cancer

Intervention

• Drug: Open-label AZD2014
  Dual TORC1/TORC2 inhibitor
• Drug: paclitaxel
  Taxane

Study Arms

Experimental: Open-label AZD2014

Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel

Interventions:

• Drug: Open-label AZD2014
• Drug: paclitaxel

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: January 27, 2017): 11
• Original Estimated Enrollment (submitted: March 26, 2015): 40
• Actual Study Completion Date: December 29, 2016
• Actual Primary Completion Date: December 29, 2016 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Histologically or cytologically proven squamous non-small cell lung cancer (NSCLC) where treatment with weekly paclitaxel is an appropriate treatment option.
2. Relapsed or refractory disease after at least one line of prior therapy. Subjects must have previously received appropriate line(s) of standard of care (SOC) treatment.
3. Measurable disease by RECIST v1.1 criteria
4. Life expectancy of at least 12 weeks.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

1. Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy, or immunotherapy during the previous 3 weeks (4 weeks for investigational medicinal products and 6 weeks for nitrosoureas and Mitomycin-C) before treatment.
2. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or Grade 1 toxicities which, in the opinion of the Investigator, should not exclude the patient.
3. Known leptomeningeal involvement, brain metastases or spinal cord compression.
4. History of hypersensitivity (> Grade 2) to active or inactive excipients of AZD2014, drugs containing Cremophor, taxanes or structurally/chemically similar drugs
5. Current refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow formulated product or previous significant bowel resection that would preclude adequate absorption of AZD2014
6. Patients with Diabetes Type I or uncontrolled Type II (HbA1c > 59 mmol/mol assessed locally) as judged by the Investigator
7. Major surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study and from which the patient has not yet recovered

8. Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening (with the exception of pegylated G-CSF (pegfilgrastim) and darbepoetin which require at least 14 days prior to screening), defined as:

   • Absolute neutrophil count 1500 cells/mm3 (1.5 x 109/L)
   • Platelet count 100.000 cells/mm3 (100 x 109/L)
   • Haemoglobin 9.0 g/dL

9. Adequate hepatic and renal function defined as:

   • Serum aspartate transaminase (AST) or alanine transaminase (ALT) 2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or 5 x ULN in the presence of liver metastases
   • Alkaline phosphatase (ALP) < 5 x ULN
   • Serum bilirubin 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
   • Estimated Creatinine Clearance 50 ml/min (Cockcroft-Gault) or serum creatinine 1.5 x ULN

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 130 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Germany, Spain, United States

Administrative Information

• NCT Number: NCT02403895
• Other Study ID Numbers: D2274C00001
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: AstraZeneca
• Original Responsible Party: Same as current
• Current Study Sponsor: AstraZeneca
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Chandra P Belani, MD; Hershey Medical Center

• PRS Account: AstraZeneca
• Verification Date: June 2018